Kresyn V I, Aryaev V L, Kostev F I
Chair of General and Clinical Pharmacology, N.I. Pirogov Medical Institute, Odessa, Ukraine.
Alcohol Alcohol. 1993 May;28(3):333-7.
Clinical data are presented on a new anti-alcoholic drug, litonit. A substantial reduction in the pathological addiction to alcohol takes place under the effect of litonit, and a stable aversive reaction to alcohol develops. The new drug is distinguished by its low toxicity, good tolerance, and its failure to cause disorders of the liver and kidneys even after chronic administration.
本文介绍了一种新型抗酒精药物利托尼特的临床数据。在利托尼特的作用下，对酒精的病理性成瘾显著降低，并且对酒精产生了稳定的厌恶反应。这种新药的特点是毒性低、耐受性好，即使长期服用也不会导致肝肾疾病。
